v3.23.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Schedule of worldwide net revenues The following table details AbbVie’s worldwide net revenues:
Three months ended
March 31,
(in millions)
20232022
Immunology
HumiraUnited States$2,948 $3,993 
International593 743 
Total$3,541 $4,736 
SkyriziUnited States$1,139 $781 
International221 159 
Total$1,360 $940 
RinvoqUnited States$449 $311 
International237 154 
Total$686 $465 
Hematologic Oncology
ImbruvicaUnited States$638 $874 
Collaboration revenues240 299 
Total$878 $1,173 
VenclextaUnited States$265 $228 
International273 245 
Total$538 $473 
Aesthetics
Botox CosmeticUnited States$409 $413 
International250 228 
Total$659 $641 
Juvederm CollectionUnited States$122 $148 
International233 262 
Total$355 $410 
Other AestheticsUnited States$246 $285 
International40 38 
Total$286 $323 
Neuroscience
Botox TherapeuticUnited States$587 $500 
International132 114 
Total$719 $614 
Vraylar
United States$560 $427 
International1 — 
Total$561 $427 
DuodopaUnited States$25 $24 
International93 97 
Total$118 $121 
UbrelvyUnited States$150 $138 
International2 — 
Total$152 $138 
QuliptaUnited States$66 $11 
Three months ended
March 31,
(in millions)
20232022
Other NeuroscienceUnited States$75 $173 
International4 4 
Total$79 $177 
Eye Care
OzurdexUnited States$39 $33 
International76 74 
Total115 107 
Lumigan/GanfortUnited States$63 $67 
International67 73 
Total$130 $140 
Alphagan/CombiganUnited States$28 $70 
International43 37 
Total$71 $107 
RestasisUnited States$79 $235 
International13 11 
Total$92 $246 
Other Eye CareUnited States$110 $91 
International90 80 
Total$200 $171 
Other Key Products
MavyretUnited States$171 $169 
International193 211 
Total$364 $380 
CreonUnited States$305 $287 
Linzess/ConstellaUnited States$251 $233 
International8 7 
Total$259 $240 
All other$691 $1,211 
Total net revenues$12,225 $13,538